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Background: Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate
cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223, is not
established.
Patients and methods: The radium-223 ALSYMPCA trial enrolled patients with CRPC and symptomatic bone metastases.
Prognostic potential of baseline variables was assessed using Cox models. Percentage changes in biomarker levels from base-
line were evaluated during the trial period; changes from baseline to week 12 were evaluated for association with OS and
surrogacy.
Results: Eastern Cooperative Oncology Group performance status, total alkaline phosphatase (tALP), lactate dehydrogenase
(LDH), and prostate-specific antigen (PSA) at baseline were associated with OS (P 0.0003) in the intent-to-treat population
(radium-223, N¼ 614; placebo, N¼ 307). tALP declined from baseline within 4 weeks after beginning radium-223, by week 12
declining in 87% of radium-223 and 23% of placebo patients (P< 0.001). LDH declined in 51% and 34% (P¼ 0.003), whereas
PSA declined in 27% and 14% (P¼ 0.160). Mean tALP change from baseline was 32.2% decrease with radium-223 and 37.2%
increase with placebo. Radium-223 patients with tALP decline from baseline to week 12 (confirmed3 weeks from week 12)
had 55% lower risk of death (hazard ratio¼ 0.45; 95% CI 0.34–0.61) versus those with no confirmed tALP decline. Proportional
treatment effect (PTE) values for tALP, LDH, and PSA changes from baseline at week 12 as OS surrogate markers were 0.34
(95% CI: 0–0.746), 0.07 (95% CI: 0–0.211), and 0 (95% CI: 0–0.082), respectively.
Conclusions: Significant tALP declines (versus placebo) occurred as early as 4 weeks after beginning radium-223 therapy.
tALP or LDH declines at 12 weeks correlated with longer OS, but did not meet statistical surrogacy requirements. Dynamic
changes in tALP and LDH during radium-223 treatments may be useful to monitor, but do not serve as surrogates for survival.
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Introduction
For individual patients with metastatic castration-resistant pros-
tate cancer (mCRPC), prognostic models based on baseline clin-
ical characteristics may be used to predict survival but are not
currently used to monitor responses to therapy [1–5]. Serial bone
scans [6] and advanced imaging methods [7] may serve this pur-
pose, but simpler, less invasive, less expensive methods are
needed to dynamically monitor therapy and inform decisions re-
garding treatment modification [8]. A surrogate marker that pre-
dicted overall survival (OS) in individual patients would be
particularly useful in decisions regarding treatment modification
[9].
Surrogacy requirements for OS in advanced prostate cancer
were met for patients receiving docetaxel therapy by prostate-
specific antigen (PSA) decreases30% after 3 weeks of treatment
in the SWOG 99-16 [10] and TAX327 [3] trials, and for patients
receiving abiraterone acetate plus prednisone therapy or prednis-
one alone by the number of circulating tumor cells (CTC) and
lactate dehydrogenase (LDH) levels after 12 weeks of treatment
[11]. These surrogates may eventually aid in monitoring therapy
with these agents, but further clinical investigation and validation
are required [10, 12]. For 70% of advanced prostate cancer pa-
tients with bone metastases [8], bone-related markers (eg, total
alkaline phosphatase [tALP]) are prognostic for OS [13–15] and
tALP changes may be an early indicator of bone progression [8].
Both PSA and tALP changes are closely associated with survival,
but PSA levels do not provide accurate information regarding ex-
tent of skeletal metastases or treatment effects on disease progres-
sion in bone. Therefore, tALP changes may correlate better with
OS than PSA [16, 17].
The phase 3 ALSYMPCA trial established radium-223 efficacy
and safety in CRPC patients with bone metastases [18, 19]. With
radium-223, versus placebo, OS improved significantly (median
14.9 versus 11.3 months; hazard ratio [HR]¼0.70; 95% confi-
dence interval [CI]: 0.58, 0.83). Time to first symptomatic skel-
etal event was significantly prolonged (median 15.6 versus
9.8 months; HR¼ 0.66; 95% CI: 0.52–0.83), and secondary end
points (including time to tALP increase, tALP response rate, and
tALP normalization rate) favored radium-223 treatment [18, 19].
For mCRPC patients treated with radium-223, tALP changes
properly established as a surrogate for survival could optimize
treatment, allowing quick change of direction of therapies to pa-
tients most likely to benefit from such changes. Thus, exploratory
analyses were conducted from ALSYMPCA to evaluate the treat-
ment effect of radium-223 on changes in tALP, LDH, and PSA
levels and assess their prognostic and predictive value.
Methods
ALSYMPCA compared efficacy and safety of radium-223 versus placebo,
each plus best standard of care, in CRPC patients with symptomatic bone
metastases [18]. Randomized patients (2:1) received six intravenous in-
jections of radium-223 (50 kBq/kg IV [55 kBq/kg IV following US
National Institutes of Standards and Technology update]) [20] or match-
ing placebo, one injection every 4 weeks. The primary end point was OS.
Univariate and multivariate analyses with Cox proportional hazards
models assessed the potential prognostic value for survival of selected
baseline variables in placebo patients, radium-223 patients, and the
intent-to-treat (ITT) population. Selected variables included prior
docetaxel, prior hormone therapy, hemoglobin, serum albumin, tALP,
PSA, LDH, Eastern Cooperative Oncology Group performance status
(ECOG PS), opiate use, and age at study entry [4]. Kaplan–Meier analy-
sis, after tertile grouping using baseline values, further illustrated the as-
sociation of baseline tALP, PSA, and LDH with OS for radium-223 and
placebo patients.
Changes from baseline in tALP, PSA, and LDH were assessed as least-
squares mean percentage change at week 12, the halfway point of treat-
ment, allowing consistency in protocol-defined timing of tALP and PSA
measurements. Waterfall plots of maximum percentage change in tALP,
LDH, and PSA from baseline to week 12 for each patient illustrated the
magnitude of treatment effect. Dynamics of mean percentage change
from baseline in biomarker levels, at each treatment visit and follow-up
visits 12 and 24 weeks after last study-drug dose, were evaluated. OS by
confirmed tALP or LDH decline at week 12 (decline confirmed3 weeks
from week 12) was evaluated. The relationship of relative risk of death to
percentage changes from baseline at week 12 (last observation carried for-
ward) was assessed using Cox proportional hazards modeling, including
all baseline covariates.
Changes in tALP, PSA, and LDH from baseline to week 12 were eval-
uated as potential measures of OS surrogacy, as defined by Prentice [9],
and quantified as a proportional treatment effect (PTE) [12]. PTE de-
scribes how much of the treatment effect on OS is explained by biomarker
changes. PTE was calculated as 1 minus the ratio of (a) HR in the Cox
proportional hazards regression model for survival with treatment
(radium-223) plus the surrogate marker (tALP, PSA, LDH) to (b) that
with treatment alone. Perfect surrogacy would be indicated by PTE¼ 1;
no surrogacy, by PTE¼ 0. CIs were calculated according to Lin et al. [12],
with a strong degree of surrogacy suggested if the 95% CI lower bound
exceeded 0.5.
Results
Baseline prognostic factors
Multivariate analysis of baseline prognostic values as continuous
variables was performed for placebo and radium-223 patients
separately and for the entire ITT population (Table 1). For
radium-223 patients, poor baseline ECOG PS and elevated base-
line values for LDH, tALP, and PSA were associated with highest
risk of death; for placebo patients, elevated baseline values for
LDH and tALP were significantly associated with an increased
risk of death. For the overall ITT population, opiate use was an
additional significant baseline prognostic variable for OS.
Kaplan–Meier analysis showed longer median survival among
radium-223 patients in the lowest tALP tertile (131 U/L), versus
those in the highest tertile (334 U/L) (23.9 versus 10.2 months);
no overlap in the 95% CIs indicated a consistent trend across sub-
groups (supplementary Figure S1A, available at Annals of
Oncology online). Placebo patients in the lowest (153 U/L) ver-
sus highest (360 U/L) tALP tertile also survived longer (median
18.8 versus 7.5 months) (supplementary Figure S1B, available at
Annals of Oncology online). Similarly, longer survival was seen for
radium-223 and placebo patients with lower versus higher base-
line LDH (supplementary Figure S1C and D, available at Annals
of Oncology online, respectively) and PSA values (data not
shown).
Post-treatment changes from baseline
Changes from baseline were assessed at week 12 for tALP, LDH,
and PSA for patients with baseline and week 12 determinations (sup
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plementary Figure S2, available at Annals of Oncology online). tALP
decreased from baseline in 87% (433/497) of radium-223 patients
versus 23% (49/211) of placebo patients (P< 0.001). For LDH,
51% (242/473) radium-223 and 34% (70/206) placebo patients
showed a decrease (P¼ 0.003). PSA declined in 27% (135/493) of
radium-223 and 14% (30/210) of placebo patients (P¼ 0.160) (sup
plementary Table S1, available at Annals of Oncology online).
Waterfall plots, showing maximum percentage change in tALP and
LDH at any time from baseline to week 12 for each patient in
radium-223 and placebo groups, illustrated the between-group
magnitude of difference in tALP response (supplementary Figure
S3A, available at Annals of Oncology online) and a similarity in
LDH response (supplementary Figure S3B, available at Annals of
Oncology online), revealing a stronger association of tALP versus
LDH declines with radium-223 treatment. No apparent difference
was seen in waterfall plots of PSA response for radium-223 versus
placebo (not shown).
Mean percentage change from baseline in tALP and LDH for
radium-223 and placebo patients through 24 weeks of radium-223
treatment and follow-up are shown in Figure 1A and B. With
radium-223, tALP decreases occurred as early as 4 weeks after
treatment initiation, remained consistently low until treatment
completion at 24 weeks, and remained significantly lower versus
placebo patients at all time points to 46 weeks (P< 0.001) (Figure
1A). With placebo, tALP increased continuously through treat-
ment and post-treatment follow-up. LDH levels for radium-223
patients were significantly lower versus placebo patients through-
out most of the 24-week treatment period, but remained above
baseline and increased through post-treatment follow-up at a rate
similar to the placebo group rate (Figure 1B).
Relationship of post-treatment changes to OS and
surrogacy
In an exploratory analysis, radium-223 patients with confirmed
tALP or LDH decline from baseline at week 12 survived longer
than those with no confirmed decline (Figure 2A and B). Among
497 patients with tALP values determined at baseline and week
12, 400 patients with a confirmed tALP decline had a median sur-
vival of 17.8 months and 55% lower risk of death (HR¼ 0.45;
95% CI: 0.34–0.61; P< 0.0001) versus 97 patients with no con-
firmed tALP decline (median survival, 10.4 months) (Figure 2A).
Baseline characteristics were similar between patients with and
those without confirmed decline. Although heavily weighted at
the lower end by number of patients experiencing a tALP de-
crease, Cox regression modeling shows a near-linear relationship
between percentage change in tALP from baseline (increase or de-
crease) at week 12 and risk of death, relative to no change in tALP
(Figure 3A). Similarly, 196 radium-223 patients with an LDH de-
cline from baseline to week 12 survived a median of 19.5 months
and had a 45% lower risk of death (HR¼ 0.55; 95% CI: 0.42–
0.73; P< 0.0001) versus 277 patients with no LDH decline (me-
dian survival, 14.5 months) (Figure 2B). Greater LDH increases,
however, were associated with exponentially rapid increase in
risk of death. Patients with a 300–400% increase in LDH at week
12 had an 7- to 14-fold greater risk than those with no LDH
change (Figure 3B). In contrast, among 493 radium-223 patients
with PSA values determined at baseline and week 12, PSA
increased in 358 (73%) patients, often by factors of 10-fold or
more. Multivariate analysis of the correlation between OS and
PSA changes at week 12 showed that the impact of PSA changes
at week 12 on risk of death was negligible (Figure 3C).
PTE values based on Cox regression models for tALP, LDH,
and PSA changes from baseline at week 12 as surrogate markers
of survival were 0.34 (95% CI: 0–0.746), 0.07 (95% CI: 0–0.211),
and 0 (95% CI: 0–0.082), respectively. tALP had the highest PTE,
but only modest surrogacy; a PTE¼ 0.34 indicates that the tALP
decrease accounted for 34% of the survival benefit from
radium-223 treatment.
Discussion
Multivariate analysis showed that elevated baseline tALP and
LDH levels were associated with higher risk of death, compared
with other factors, in placebo patients who did not receive
Table 1. Multivariate analysis of the correlation of baseline covariates
with overall survivala
Baseline variable HRb P valuec
Placebo patients
Albumin 0.970 0.0652
ECOG PS (2 versus 0 or 1) 1.441 0.0839
Log LDHd 2.632 0.0043
Log tALPd 2.332 <0.0001
Log PSAd 1.250 0.0569
Age 1.009 0.3804
Radium-223 patients
Albumin 0.972 0.0224
ECOG PS (2 versus 0 or 1) 1.775 0.0002
Log LDHd 4.244 <0.0001
Log tALPd 1.857 0.0001
Log PSAd 1.498 <0.0001
Age 1.018 0.0172
Overall ITT population
Randomized treatment group 0.779 0.0074
Albumin 0.974 0.0069
ECOG PS (2 versus 0 or 1) 1.576 0.0003
Log LDHd 3.407 <0.0001
Log tALPd 2.017 <0.0001
Log PSAd 1.405 <0.0001
Age 1.016 0.0080
Opiate use (yes or no) 1.214 0.0379
aBaseline factors signiﬁcantly associated with survival by univariate
analysis were included in the multivariate analysis.
bHRs are relative risk for a 1-unit increase in the baseline variable for
those without log transformation, or a 10-fold increase for those with
log transformation.
cBased on Cox proportional hazards model.
dLog transformation was performed for baseline variables with heavily
skewed distributions.
ECOG PS, Eastern Cooperative Oncology Group performance status;
HR, hazard ratio; LDH, lactate dehydrogenase; ITT, intent-to-treat; PSA,
prostate-speciﬁc antigen; tALP, total alkaline phosphatase.
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radium-223 treatment, as well as in radium-223-treated patients
and the entire ITT population. Our findings for mCRPC patients
with bone-only disease are consistent with similar studies in less
defined populations and highlight the relative importance of
tALP in this setting [2–5].
In ALSYMPCA, radium-223 treatment prolonged survival for
patients with CRPC and bone-only metastases [18]. In this post
hoc analysis, we report confirmed tALP declines in 80% of evalu-
able patients after 12 weeks of receiving radium-223 and their as-
sociation with decreased risk of death, suggesting that changes in
tALP could potentially be a surrogate for survival useful in man-
aging patients receiving radium-223 therapy. The ALSYMPCA
findings meet the requirements for a surrogacy analysis as
described by Prentice [9]. PTE surrogacy analysis showed tALP
decreases at 12 weeks from baseline to be a moderate predictor of
survival, with PTE¼ 0.34 and a broad CI (0.0, 0.746). The
analysis also indicated that radium-223 effects on LDH or PSA
contributed little or nothing to the radium-223-associated sur-
vival benefit. Our tALP findings were consistent with those re-
ported in TAX327, which showed an association with OS but
could not establish surrogacy for tALP changes in patients with
bone metastases [16].
Responses to chemotherapy are likely related to a combination
of factors: the patient’s underlying physical condition and prob-
ably other factors reflected or not in biomarker levels, such as
pain score and visceral organ involvement. Scher and colleagues
[11], in their phase 3 study of abiraterone acetate–prednisone, re-
ported a high level of surrogacy for a biomarker panel consisting
of the combination of circulating tumor cell (CTC) count and
LDH level at 12 weeks. They used Prentice criteria [9] to establish
relative surrogacy, but did not assess PTE. The CTC-LDH com-
bination was superior to CTC or LDH alone or to CTC
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Figure 1. tALP and LDH dynamics in the ITT population. Mean percentage change in (A) baseline tALP and (B) baseline LDH at the end of each treatment cycle (6 cycles) and two follow-up
visits. Six patients in the radium-223 arm and 1 in the placebo arm did not have baseline LDH determinations and were excluded from this analysis. ITT, intent to treat; LDH, lactate dehydrogenase;
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combination with any other biomarkers, including tALP de-
creases and30% or50% PSA decreases. Future assessments of
the validity of markers in predicting effectiveness of chemother-
apy may be more successful when combinations of factors are
considered.
Limitations in our study influenced our conclusions: The ex-
ploratory analysis was not included in the original ALSYMPCA
study plan; other relevant bone markers and markers such as
CTCs, not prospectively determined in this phase 3 study, could
not be considered. We analyzed only biomarker level decreases
from baseline to 12 weeks. If we considered specific rates of de-
cline, as in the PSA studies, we may have arrived at a higher PTE
value, but the patient number in each group may have been inad-
equate for statistical analysis. We evaluated markers individually,
not in combination; the proportion of patients showing LDH
and PSA decreases did not appear to justify the more extensive
analysis. Future prospective studies addressing these limitations
may identify more promising candidates for surrogacy. With
these caveats, we found that changes in tALP, LDH, and PSA
levels after 12 weeks of treatment are not surrogates for survival
for patients with CRPC and bone metastases treated with
radium-223. The effective course of radium-223 treatment in
ALSYMPCA was 24 weeks, with 6 cycles given at 4-week intervals.
Using biomarker changes, particularly rising PSA levels, to make
decisions about continuing radium-223 presents a substantial
risk that a large fraction of patients who may benefit will be
denied effective treatment. Monitoring biomarkers during treat-
ment may have benefit as an indication for radiologic evaluation
of disease status [8].
The observed tALP changes with treatment raise questions
about radium-223 treatment duration and underline the need for
a reliable marker of radium-223 efficacy. In ALSYMPCA with
radium-223, the rapid and sustained tALP declines and the
increasing tALP suppression with continued therapy reflected the
radionuclide mechanism of action in the bone microenviron-
ment, consistent with rapid and progressive inhibition of ALP
production by osteoblasts. Dynamic profiles of both tALP and
LDH levels during the study suggest that treatment durations
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>24 weeks should be tested. Although we could not determine
whether tALP changes were a direct effect on cancer cells or on
osteoblasts, preclinical studies suggest that tALP is a marker of
pharmacodynamic effect and that radium-223 impacts both
osteoblasts and tumor cells [21, 22]. In a human prostate cancer
model, characterized by osteoblastic growth, PSA production,
and systemic metastases when inoculated into the bone marrow
cavity, radium-223 inhibited disease progression, reduced tumor
volume, and decreased areas of tumor in tumor-bearing tibias.
Tumor-induced osteoblastic bone growth was suppressed and
normal architecture was maintained, leading to reduced bone
volume in tumor-bearing bone. Radium-223 induced double-
strand DNA breaks in tumor cells and osteoclasts, consistent with
potent radiation effects of radium-223 in the tumor micro-
environment [21, 22]. Such models in prostate cancer, and others
in breast cancer [23], are important in addressing questions
about radium-223 mode of action in cancer patients.
In conclusion, significant tALP declines (versus placebo)
occurred as early as 4 weeks after initiation of radium-223 ther-
apy. tALP or LDH decline at 12 weeks correlated with longer OS,
but did not meet statistical surrogacy requirements. Changes in
tALP and LDH are dynamic during radium-223 treatments and
may be useful to monitor, but do not serve as surrogates for
survival.
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